KLISYRI® is a microtubule inhibitor
Transcript
Tirbanibulin ointment 1% is a novel topical microtubule inhibitor approved for the treatment of actinic keratosis of the face or scalp.
Microtubules play a role in many cellular processes.
They are involved in the cell cycle to pull chromosomes apart during cell division or mitosis.
Tirbanibulin selectively binds to tubulin dimers and inhibits tubulin polymerization, leading to the disruption of the cellular microtubular network.
Disruption of microtubules leads to cell cycle arrest, particularly in rapidly dividing cells.
© Copyright 2024
All Rights Reserved.
Almirall, LLC. 101 Lindenwood Drive, Ste 400, Malvern, PA 19355
US-TIRBA-2400055 06/2024
IMPORTANT SAFETY INFORMATION
INDICATION
KLISYRI is a microtubule inhibitor indicated for the topical field treatment of actinic keratosis on the face or scalp.
IMPORTANT SAFETY INFORMATION
WARNINGS AND PRECAUTIONS
Ophthalmic Adverse Reactions
KLISYRI may cause eye irritation. Avoid transfer of the drug into the eyes and to the periocular area during and after application. Wash hands immediately after application. If accidental exposure occurs, instruct patient to flush eyes with water and seek medical care as soon as possible.
Local Skin Reactions
Local skin reactions, including severe reactions (erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration) in the treated area can occur after topical application of KLISYRI. Occlusion after topical application of KLISYRI is more likely to result in irritation. Avoid use until skin is healed from any previous drug, procedure, or surgical treatment.
ADVERSE REACTIONS
The most common adverse reactions (incidence ≥2%) were local skin reactions, application site pruritus, and application site pain.
Please see full Prescribing Information.
To report an adverse event or product complaint, call or email Medical Affairs and Customer Relations • Phone: 1-866-665-2782• Fax: 510-595-8183 •
Email: almirallmc@eversana.com